One personal injury firm has filed more than 90 New Jersey suits claiming Novo Nordisk's Ozempic and Wegovy caused sudden vision loss. Denmark has awarded about $55,600 a patient for the same injury, the only price on record, while studies of whether the drugs cause it still disagree.
Reality
- Evidence45
- Adoption
- Insufficient
- Hype gap+10
- Incentives65
- Confidence50
The FDA is investigating whether GLP-1 drugs cause sudden vision loss, and the New Jersey filings number in the dozens. The market those drugs sell into is projected at $92 billion this year.
Reality
- Evidence45
- Adoption74
- Hype gap+14
- Incentives62
- Confidence42
More than 90 New Jersey suits and dozens more against Novo Nordisk and Eli Lilly turn on a warning the FDA has not written while four other jurisdictions added theirs. Denmark's payouts are the only money that has moved so far.
Reality
- Evidence45
- Adoption55
- Hype gap+20
- Incentives65
- Confidence45
In a new NBER working paper, Robert Kaestner and Cuiping Schiman followed adults with diabetes through 12 years of federal survey data and found little measurable change in depression, distress, employment or marriage.
Reality
- Evidence45
- Adoption
- Insufficient
- Hype gap+10
- Incentives40
- Confidence50
The Danish drugmaker will test Anthropic's science workbench on specific R&D workflows while an earlier company-wide OpenAI agreement keeps running alongside it. Bloomberg reported that financial terms were not disclosed.
Reality
- Evidence52
- Adoption22
- Hype gap+45
- Incentives82
- Confidence58
The Federal Reserve says reaching customers is the top operational problem for small employers. One owner's account suggests part of that problem is detection, and the proximity that catches such signals is the first thing growth takes away.
Reality
- Evidence34
- Adoption
- Insufficient
- Hype gap+18
- Incentives55
- Confidence44
A Yale mouse study in PNAS reports that semaglutide activates AgRP neurons, and that animals lacking those neurons cannot sustain fat loss on the drug.
Reality
- Evidence44
- Adoption
- Insufficient
- Hype gap+34
- Incentives62
- Confidence46
A 2026 JAMA Surgery analysis shows surgical obesity care losing a third of its volume in two years. The spend has not vanished; it has moved to the pharmacy benefit, where coverage decides who gets treated.
Reality
- Evidence56
- Adoption74
- Hype gap+14
- Incentives66
- Confidence54
Nagoya University and FUJIFILM report longer-lasting expression from capped circular RNA in a new lipid nanoparticle. The mouse data are directional; the duration numbers are not public yet.
Reality
- Evidence42
- Adoption
- Insufficient
- Hype gap+34
- Incentives62
- Confidence40
An advisory panel voted to route peptides marketed for sleep, wound healing and cognition through compounding pharmacies, which face less oversight and may dispense unapproved drugs.
Reality
- Evidence60
- Adoption45
- Hype gap+35
- Incentives70
- Confidence50
Orforglipron's approval takes peptide manufacturing and refrigeration off the constraint list. What replaces them is prescribing capacity in primary care and daily adherence.
Reality
- Evidence42
- Adoption48
- Hype gap+28
- Incentives58
- Confidence40
A Cambridge mouse study locates the GIP paradox in anatomy: agonists act through the brainstem, antagonists release a hypothalamic brake. Combination design becomes a targeting question.
Reality
- Evidence52
- Adoption34
- Hype gap+22
- Incentives62
- Confidence50